Annexon, Inc.
ANNX NasdaqΒ· Pharmaceutical Preparations
Last close Β· Oct 27, 2026
$3.76
KIRA Β· Stoqlyβs AI analyst, in plain words
- Annexon, Inc. lost $207M in fiscal 2025.
- Free cash flow was β$186M in fiscal 2025, β of revenue.
Market cap
$756M
P/E
β
Revenue
β
Net income
β$207M
Free cash flow
β$186M
Operating margin
β
Annexon, Inc. in 30 seconds Β· fiscal 2025
Does it make a profit?
β$207M
No. It lost money last year.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
What Annexon, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 30, 2026
- Legal name
- Annexon, Inc.
- CIK
- 0001528115
Annexon, Inc. Β· ANNX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | β$130M | β$142M | β$134M | β$138M | β$207M |
| Diluted EPS | β$3.40 | β$2.60 | β$1.77 | β$1.01 | β$1.34 |
| Cash | |||||
| Cash from operations | β$106M | β$116M | β$121M | β$118M | β$186M |
| Capital expenditure | $1.7M | $6.5M | $0.2M | $0.0M | $0.1M |
| Free cash flow | β$108M | β$123M | β$121M | β$118M | β$186M |
| Share count change | 125.9% | 42.7% | 38.4% | 81.6% | 12.9% |
| Debt and strength | |||||
| Cash and short-term investments | $243M | $243M | $260M | $312M | $238M |
| Shareholders' equity | $232M | $231M | $251M | $293M | $212M |
| Current ratio | 11.4x | 11.1x | 14.7x | 10.4x | 5.7x |
| Returns and quality | |||||
| Return on equity | β45.2% | β61.3% | β55.7% | β50.8% | β81.9% |
| Return on tangible equity | β56.2% | β61.4% | β53.6% | β47.2% | β98.5% |
| Altman Z'' | 3.2 | 1.3 | 1.5 | 1.2 | β7.9 |
Insiders bought, 12 months
$12.4M
4 insiders
Insiders sold, 12 months
$0.3M
5 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Annexon, Inc. Β· ANNX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.76 a share, the company is worth $756M.
Source: SEC EDGAR XBRL filings (CIK 0001528115). Data updated October 24, 2026. For information only β not investment advice. Check the original filings before relying on any figure.
